Basic/Clinical Science Session
Extracellular Matrix Pathobiology in CKD and Alport Syndrome
November 04, 2022 | 02:00 PM - 04:00 PM
Location: WF1 Tangerine, Orange County Convention Center, West Building
Session Description
Genetic studies in disease- and population-based cohorts have expanded the clinical spectrum associated with pathogenic variants in type IV collagen. This has highlighted a need to understand the extracellular matrix (ECM) and its role in filtration function. This session explores the patient perspective on research and education in the area, biologic mechanisms linking the ECM to glomerular filtration, and model systems. Considerations for potential therapeutic approaches are also discussed, including gene editing.
Learning Objective(s)
- Summarize research and education priorities important to the Alport syndrome community
- Outline the composition of the ECM in health, aging, and disease
- List gene editing strategies for Alport syndrome
- Identify therapeutic strategies in Alport syndrome
Learning Pathway(s)
- Genetic Diseases and Development
Moderators
- Tomoko Horinouchi, MD, PhD
- Roser Torra, MD, PhD
Presentations
- Update on the Alport Syndrome Community, Research, and Education Efforts
02:00 PM - 02:30 PM
B. Andre Weinstock, PhD
- Kidney Basement Membrane Composition, Regulators, and Human Disease Associations
02:30 PM - 03:00 PM
Rachel Lennon, MBBS, PhD
- Developing Gene Editing Approaches in Alport Syndrome
03:00 PM - 03:30 PM
Jeffrey H. Miner, PhD, FASN
- Therapeutic Development in Alport Syndrome
03:30 PM - 04:00 PM
Oliver Gross, DrMed
